

# **EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer**

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023.

"Receipt of appropriate reimbursement from the Swiss healthcare authorities is another acknowledgment of the growing, worldwide acceptance of HIFU as an effective treatment option for men diagnosed with prostate cancer," remarked Ryan Rhodes, Chief Executive Officer of EDAP TMS. "We expect this change will result in a growing awareness of HIFU as an important treatment option in Switzerland, which should lead to more patient demand for Focal One® Robotic HIFU procedures. Additionally, increasing access to Focal One in Switzerland may signal greater momentum in Europe for hospitals and payors to support HIFU as an integral part of the comprehensive management of prostate cancer."